RHYTHM PHARMACEUTICALS, INC. Net Income
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Net Income of -$49.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$49.30M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$55.64M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $148.84M, a 31.43% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$52.90M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2020 was -$134.00M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2019 was -$140.73M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2018 was -$74.06M.
- RHYTHM PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2017 was -$33.71M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$49.30M 10-Q · filed 2026-08-04 | -$104.94M 10-Q · filed 2026-08-04 | $43.90M derived: sum of 3 quarters · filed 2026-08-04 | -$9.00M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | -$55.64M 10-Q · filed 2026-08-04 | $93.20M derived: sum of 2 quarters · filed 2026-08-04 | $40.29M derived: sum of 3 quarters · filed 2026-08-04 | -$6.34M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-12-31 | $148.84M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | $95.93M derived: sum of 2 quarters · filed 2026-04-29 | $49.30M derived: sum of 3 quarters · filed 2026-08-04 | -$196.54K DEF 14A · filed 2026-04-29 | -$196.54M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$52.90M 10-Q · filed 2025-11-04 | -$99.54M derived: sum of 2 quarters · filed 2026-08-04 | -$149.03M 10-Q · filed 2025-11-04 | $68.02M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-06-30 | -$46.63M 10-Q · filed 2026-08-04 | -$96.13M 10-Q · filed 2026-08-04 | $120.92M derived: sum of 3 quarters · filed 2026-08-04 | $77.28M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2025-03-31 | -$49.50M 10-Q · filed 2026-08-04 | $167.55M derived: sum of 2 quarters · filed 2026-08-04 | $123.91M derived: sum of 3 quarters · filed 2026-08-04 | $91.65M derived: sum of 4 quarters · filed 2026-08-04 | |
| 2024-12-31 | $217.05M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | $173.41M derived: sum of 2 quarters · filed 2026-04-29 | $141.15M derived: sum of 3 quarters · filed 2026-04-29 | -$260.60K DEF 14A · filed 2026-04-29 | -$260.60M 10-K · filed 2025-02-28 |
| 2024-09-30 | -$43.64M 10-Q · filed 2025-11-04 | -$75.90M derived: sum of 2 quarters · filed 2025-11-04 | -$217.31M 10-Q · filed 2025-11-04 | -$74.41M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-06-30 | -$32.26M 10-Q · filed 2025-11-04 | -$173.63M 10-Q · filed 2025-08-05 | -$30.77M derived: sum of 3 quarters · filed 2026-04-29 | -$74.94M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2024-03-31 | -$141.37M 10-Q · filed 2025-11-04 | $1.49M derived: sum of 2 quarters · filed 2026-04-29 | -$42.67M derived: sum of 3 quarters · filed 2026-04-29 | -$89.38M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2023-12-31 | $142.86M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | $98.70M derived: sum of 2 quarters · filed 2026-04-29 | $51.99M derived: sum of 3 quarters · filed 2026-04-29 | -$184.68K DEF 14A · filed 2026-04-29 | -$184.68M 10-K · filed 2024-02-29 |
| 2023-09-30 | -$44.16M 10-Q · filed 2024-11-06 | -$90.87M derived: sum of 2 quarters · filed 2024-11-06 | -$143.04M 10-Q · filed 2024-11-06 | -$4.60M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2023-06-30 | -$46.70M 10-Q · filed 2024-11-06 | -$98.88M 10-Q · filed 2024-08-06 | $39.56M derived: sum of 3 quarters · filed 2026-04-29 | -$1.30M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2023-03-31 | -$52.18M 10-Q · filed 2024-11-06 | $86.27M derived: sum of 2 quarters · filed 2026-04-29 | $45.40M derived: sum of 3 quarters · filed 2026-04-29 | $403.88K derived: sum of 4 quarters · filed 2026-04-29 | |
| 2022-12-31 | $138.44M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | $97.58M derived: sum of 2 quarters · filed 2026-04-29 | $52.58M derived: sum of 3 quarters · filed 2026-04-29 | -$181.12K DEF 14A · filed 2026-04-29 | -$181.12M 10-K · filed 2023-03-01 |
| 2022-09-30 | -$40.86M 10-Q · filed 2023-11-08 | -$85.86M derived: sum of 2 quarters · filed 2023-11-08 | -$138.63M 10-Q · filed 2023-11-08 | -$111.95M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2022-06-30 | -$45.00M 10-Q · filed 2023-11-08 | -$97.77M 10-Q · filed 2023-08-01 | -$71.09M derived: sum of 3 quarters · filed 2026-04-29 | -$106.20M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2022-03-31 | -$52.76M 10-Q · filed 2023-11-08 | -$26.09M derived: sum of 2 quarters · filed 2026-04-29 | -$61.19M derived: sum of 3 quarters · filed 2026-04-29 | -$96.58M derived: sum of 4 quarters · filed 2026-04-29 | |
| 2021-12-31 | $26.68M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29 | -$8.43M derived: sum of 2 quarters · filed 2026-04-29 | -$43.82M derived: sum of 3 quarters · filed 2026-04-29 | -$69.61K DEF 14A · filed 2026-04-29 | -$69.61M 10-K · filed 2022-03-01 |
| 2021-09-30 | -$35.11M 10-Q · filed 2022-11-08 | -$70.50M derived: sum of 2 quarters · filed 2022-11-08 | -$26.75M 10-Q · filed 2022-11-08 | -$61.64M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$35.39M 10-Q · filed 2022-11-08 | $8.36M 10-Q · filed 2022-08-03 | -$26.54M derived: sum of 3 quarters · filed 2023-03-01 | -$60.35M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | $43.75M 10-Q · filed 2022-11-08 | $8.85M derived: sum of 2 quarters · filed 2023-03-01 | -$24.96M derived: sum of 3 quarters · filed 2023-03-01 | -$56.08M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$34.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$68.72M derived: sum of 2 quarters · filed 2023-03-01 | -$99.83M derived: sum of 3 quarters · filed 2023-03-01 | -$134.00M 10-K · filed 2023-03-01 | |
| 2020-09-30 | -$33.82M 10-Q · filed 2021-11-02 | -$64.94M derived: sum of 2 quarters · filed 2021-11-02 | -$99.10M 10-Q · filed 2021-11-02 | -$132.06M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-06-30 | -$31.12M 10-Q · filed 2021-11-02 | -$65.28M 10-Q · filed 2021-08-03 | -$98.24M derived: sum of 3 quarters · filed 2021-11-02 | -$134.24M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-03-31 | -$34.16M 10-Q · filed 2021-11-02 | -$67.12M derived: sum of 2 quarters · filed 2021-11-02 | -$103.12M derived: sum of 3 quarters · filed 2021-11-02 | -$145.92M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2019-12-31 | -$32.96M 10-K · filed 2020-03-02 | -$68.96M derived: sum of 2 quarters · filed 2020-11-02 | -$111.75M derived: sum of 3 quarters · filed 2020-11-02 | -$140.73M 10-K · filed 2022-03-01 | |
| 2019-09-30 | -$36.00M 10-Q · filed 2020-11-02 | -$78.80M derived: sum of 2 quarters · filed 2020-11-02 | -$107.77M 10-Q · filed 2020-11-02 | -$133.28M derived: sum of 4 quarters · filed 2020-11-02 | |
| 2019-06-30 | -$42.80M 10-Q · filed 2020-08-03 | -$71.77M 10-Q · filed 2020-08-03 | -$97.28M derived: sum of 3 quarters · filed 2020-08-03 | -$114.96M derived: sum of 4 quarters · filed 2020-08-03 | |
| 2019-03-31 | -$28.97M 10-Q · filed 2020-05-04 | -$54.48M derived: sum of 2 quarters · filed 2020-05-04 | -$72.17M derived: sum of 3 quarters · filed 2020-05-04 | -$86.58M derived: sum of 4 quarters · filed 2020-05-04 | |
| 2018-12-31 | -$25.51M 10-K · filed 2020-03-02 | -$43.19M derived: sum of 2 quarters · filed 2020-03-02 | -$57.60M derived: sum of 3 quarters · filed 2020-03-02 | -$74.06M 10-K · filed 2020-03-02 | |
| 2018-09-30 | -$17.69M 10-K · filed 2020-03-02 | -$32.10M derived: sum of 2 quarters · filed 2020-03-02 | -$48.56M derived: sum of 3 quarters · filed 2020-03-02 | ||
| 2018-06-30 | -$14.41M 10-K · filed 2020-03-02 | -$30.87M derived: sum of 2 quarters · filed 2020-03-02 | |||
| 2018-03-31 | -$16.46M 10-K · filed 2020-03-02 | ||||
| 2017-12-31 | -$33.71M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |